Jonas Kulhavy

机构：Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg · ORCID：0000-0002-8837-1687

发表论文 14 篇 · 总被引 117 次 · h-index 4

代表论文

• Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (2023 · Journal of Thoracic Oncology · 被引 49)
• Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy (2024 · European Journal of Cancer · 被引 28)
• Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy (2025 · Journal of Thoracic Oncology · 被引 18)
• Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany (2025 · ESMO Open · 被引 4)
• Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024 · European Journal of Cancer · 被引 4)
• PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) (2025 · Annals of Oncology · 被引 3)